Technology
Health
Pharmaceutical

Clearside Biomedical

$1.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-4.55%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell CLSD and other stocks, options, ETFs, and crypto commission-free!

About

Clearside Biomedical, Inc. Common Stock, also called Clearside Biomedical, is a clinical stage biopharmaceutical company, which engages in the development of drug therapies to treat blinding diseases of the eye. Read More Its pipeline includes Suprachoroidal CLS-TA, Suprachoroidal, Suprachoroidal CLS-TA, and gene therapy. The company was founded by Samir Kumar Patel, Vladimir Zarnitsyn, Mark Prausnitz, Daniel H. White, and Henry F. Edelhauser in May 2011 and is headquartered in Alpharetta, GA.

Employees
50
Headquarters
Alpharetta, Georgia
Founded
2011
Market Cap
49.46M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
583.41K
High Today
$1.58
Low Today
$1.46
Open Price
$1.55
Volume
340.75K
52 Week High
$15.33
52 Week Low
$0.99

Collections

Technology
Health
Pharmaceutical
Medical
Biopharmaceutical
Therapy
2016 IPO
US

News

Seeking AlphaMar 12

Clearside Biomedical, Inc. (CLSD) CEO Daniel White on Q4 2018 Results - Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2018 Earnings Conference Call March 12, 2019 5:00 PM ET Company Participants Jenny Kobin - Investor Relations Daniel White - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer Brion Raymond - Chief Commercial Officer Charlie Deignan - CFO Conference Call Participants Tessa Romero - JPMorgan Nick Rubino - Stifel Liana Moussatos - Wedbush Securities Tian Sun - Needham François Brisebois - Laidlaw Operator Good day, ladies and gen...

311
Associated PressMar 12

Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation. - Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host Webcast and Conference Call Today at 5:00 PM ET - ...

149
MarketBeatMar 7

Stock Price, News, & Analysis for Clearside Biomedical

Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vas...

14

Earnings

-$0.75
-$0.64
-$0.52
-$0.41
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.57 per share
Actual
-$0.68 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.